Clinical Trial Update: Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating silmitasertib (CX-4945) in combination with chemotherapy for relapsed or refractory solid tumors; Phase 1 and Phase 2 are currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Liposarcoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma

Drugs mentioned

• Silmitasertib (CX-4945)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Neuroblastoma, Ewing Sarcoma | Phase 1, Phase 2 | Status: RECRUITING